July 17 (Reuters) - Imugene Ltd IMU.AX :
* IMUGENE- RECEIVES SECOND ETHICS APPROVAL TO START PHASE I CLINICAL TRIAL OF NEW CANCER IMMUNOTHERAPY PD1-VAXX IN AUSTRALIA
July 17 (Reuters) - Imugene Ltd IMU.AX :
* IMUGENE- RECEIVES SECOND ETHICS APPROVAL TO START PHASE I CLINICAL TRIAL OF NEW CANCER IMMUNOTHERAPY PD1-VAXX IN AUSTRALIA